Blissco Orders Additional High CBD Hemp Following Successful CBD Oil Extraction
Not for distribution in the U.S. or to U.S. Newswires
VANCOUVER, British Columbia, April 17, 2019 (GLOBE NEWSWIRE) -- Blissco Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B), (“Blissco”) or the (“Company”) is a Canadian wellness cannabis brand based in British Columbia, a licensed processor, and producer of premium dried cannabis and cannabis oil and a licensed distributor of dried cannabis products. The Company is pleased to announce that it has successfully manufactured premium CBD oil for R&D purposes by running hemp through extraction cycles.
"Based on the success of our R&D batch run we have now purchased additional hemp from which we will begin to extract high-quality, high-CBD oil and then process it in our licensed CO2 oil lab. Blissco completes extensive due diligence on our supply chain partners to ensure that no contaminants or pesticides are ever introduced into our facility, which is also in the midst of EU GMP certification,” said Damian Kettlewell. “We are pleased with the results that we have achieved since earning our cannabis oil production license eight months ago, as well as the encouraging Certificate of Analysis from one of our licensed lab partners that we have received."
CBD oil is in high demand, with many retailers selling out quickly, the market for the product is expected to continue to grow to be worth as much as $16 billion by 2025.
About Blissco Cannabis Corp.
Blissco Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B) is a Canadian wellness cannabis brand based in British Columbia and a multi-licensed processor, cultivator, and distributor of premium cannabis.
Blissco owns and operates an 18,000 square foot, state-of-the-art facility located in Metro Vancouver, British Columbia with extraction, processing and cultivation and rooms. Blissco is supplying premium cannabis and Reserve whole flower and dried flower pre-rolls to the Canadian market with supply agreements in British Columbia, Alberta, Saskatchewan, and New Brunswick.
In support of Blissco’s global distribution strategy, the company has initiated its EU GMP certification process and has completed its first inspection by German authorities.
With a licence to process cannabis oil earned in August 2018, Blissco’s extraction lab is also in operation preparing a line of full spectrum oils for distribution in 2019.
For further information please contact: 1 604 484-9119 investors@blissco.com
Cautionary Statements
This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the word “will” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.
The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
Source: GlobeNewswire
(April 17, 2019 - 8:00 AM EDT)
